Astrazeneca granted accelerated assessment of Covid candidate
Astrazeneca announced in May that phase III data with its potential Covid-19 treatment sipavibart showed a statistically significant reduction in the incidence of Covid-19 in an immunocompromised patient population.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
CHMP recommends ten new medicines in June
For subscribers
Biotech firm raises USD 30m for weight-loss candidate
For subscribers